ESTRO 2024 - Abstract Book

S2615

Clinical - Urology

ESTRO 2024

SRT schemes with or without androgen deprivation treatment. Data about late toxicities were available for all patients included in the studies considered, whereas acute toxicity were available for 464 patients (81.4%).

For acute GU toxicities, grade 2 and grade 3 were observed in 11.2% (52/464) and 2.8% (13/464) of the patients, respectively. Late GU toxicity rates remained stable with 9.8% (56/570) of patients experiencing grade 2 GU toxicity and 3.3% (19/570) with late grade 3 GU toxicity. Acute GI toxicity grade 2 was reported in 8.4% (39/464) with no acute grade 3 or grade 4 toxicity. Furthermore, late GI toxicity rates exhibited a decrease, with 5.1% (29/570) of patients encountering grade 2 toxicity, yet a small minority of 0.5% (3/570) presented with grade 3 GU toxicity.

Conclusion:

Overall, SRT appears to be safe in patients with prostate cancer who underwent primary focal treatment, with very low rates of severe acute and late GU/GI toxicities.

Keywords: Salvage Radiation, Focal Failure, prostate cancer.

3097

Digital Poster

Stereotactic body radiation therapy for prostate cancer: early results of an all-risk patient cohort

Gabriel Lazcano Álvarez 1,2 , Lisset González Abascal 3 , Tomás Walter Martin 3 , Ilan Perrot Rosenberg 3,2 , Gabriel Veillon Contreras 3,2 , Benjamin Tudela Staub 3,2 , Ximena Quintela Dávila 3,2 , José Solís Campos 3,2 1 Universidad de Valparaíso, Public Health, Valparaíso, Chile. 2 Carlos Van Buren Hospital, Oncology, Valparaíso, Chile. 3 Universidad de Valparaíso, Oncology, Valparaíso, Chile

Purpose/Objective:

Stereotactic body radiation therapy (SBRT) is an emerging standard for radical treatment of localized prostate cancer. The purpose of this study is to describe early efficacy and toxicity results of a cohort of patients treated by this technique at Hospital Carlos Van Buren (Valparaiso, Chile).

Material/Methods:

This is a retrospective, single center cohort composed of patients treated between 2020 and 2022. SBRT prescription was 36,25 Gy in 5 fractions to the whole prostate, with at least 80% of the CTV receiving 40 Gy. Seminal vesicles weren't treated in low risk patients, while intermediate and high risk groups received 27.25 Gy to the proximal 1 and 2 cm, respectively. No nodal groups were treated. CT and 1.5T MRI T2 planning images were acquired and co-registered. Urethral catheters, fiducials or rectal spacers weren´t utilized. Treatment was